{'fraction_non_alphanumeric': 0.03745318352059925, 'fraction_numerical': 0.014044943820224719, 'mean_word_length': 5.6397515527950315, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vogt–Koyanagi–Harada disease‐like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma

Dear Editor, Vogt–Koyanagi–Harada (VKH) disease is a systemic autoimmune disorder caused by autoimmune responses directed against melanocyte-associated antigens in the target organs. Here, we report a very rare case of VKH disease induced by vemurafenib therapy against metastatic cutaneous malignant melanoma. A 51-year-old Japanese woman presented with a welldemarcated black macule on the right inner ankle. Under the diagnosis of malignant melanoma, the patient underwent surgical resection and total lymph node dissection (pT2b, N1a, M0, stage IIIB). Despite postoperative DAV-Feron therapy (dacarbazine, nimustine, vincristine and interferon-b), multiple lung and lymph node metastases were observed 4 years after surgery. After the confirmation of BRAF V600E mutation in tumor cells, vemurafenib therapy was started at 1920 mg/day. However, skin rash due to vemurafenib was observed as tender erythema (Fig. 1a) and follicular papules (Fig. 1b) on the